Drugs / VS-4718
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02651727 | Sep 2015 → Jan 2017 | malignant pancreatic neoplasm | Verastem, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT01849744 | Jun 2013 → Apr 2017 | metastatic malignant neoplasm | Verastem, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT02215629 | ? → Sep 2016 | B-cell acute lymphoblastic leukemia, acute myeloid leukemia | Verastem, Inc. | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2026-03-17 | Verastem, Inc. | Results Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026 verastem.com ↗
In mutant BRAF-driven models, the combination of the FAK inhibitor VS-4718 and the RAF/MEK clamp avutometinib, with or without the mutant BRAF inhibitor encorafenib, significantly delayed tumor onset, induced regression of established tumors and brain metastases, and prolonged overall survival. |
| 2016-07-05 | Verastem, Inc. | Results Study Published in Nature Medicine Highlights Potential Role of FAK Inhibition in Pancreatic Cancer verastem.com ↗
It was then demonstrated that single-agent treatment with Verastem’s FAK inhibitor VS-4718 significantly limited tumor progression, resulting in a doubling of survival in an in vivo model of human PDAC. |
| 2016-03-30 | Verastem, Inc. | Results Verastem Announces Presentation of Scientific Data Supporting FAK Inhibition in Combination with Immunotherapy at the Keystone Symposium on Cancer Pathophysiology verastem.com ↗
Our data show that Verastem’s FAK inhibitor dramatically reduced tumor stroma and reduced numbers of immunosuppressive cells in pancreatic cancer models. |
| 2016-03-16 | Verastem, Inc. | Results Verastem to Present Data Supporting FAK/PYK2 Inhibition at the 2016 American Academy of Cancer Research Annual Meeting verastem.com ↗
Key immune-related observations include VS-6063 and VS-4718 dose-dependently stimulating proliferation of CD8+ cytotoxic T cells. |
| 2016-03-10 | Verastem, Inc. | Results Verastem to Present Scientific Data Supporting FAK and PI3K/mTOR Inhibition to Target Cancer Stem Cells at the Keystone Symposium on Stem Cells and Cancer verastem.com ↗
New data from preclinical models presented today demonstrate that FAK inhibition enhances the anti-tumor effect of adoptive T cell transfer. |
| 2015-04-22 | Verastem, Inc. | Results Verastem Presents Encouraging Scientific Data on the Preferential Targeting of Cancer Stem Cells at the 2015 American Association of Cancer Research Annual Meeting verastem.com ↗
The data presented provide continued evidence that VS-6063, VS-4718 and VS-5584 effectively target cancer stem cells, reduce tumor initiating capability and prolong the anti-tumor response to standard of care chemotherapy in preclinical models of multiple tumor types. |
| 2014-12-11 | Verastem, Inc. | Results Verastem Presents Data at the 2014 San Antonio Breast Cancer Symposium verastem.com ↗
Our new data demonstrate the functional relevance of the effective knock down of cancer stem cells by our FAK inhibitors, VS-6063 and VS-4718, in preclinical models of triple negative breast cancer. |
| 2014-12-08 | Verastem, Inc. | Results Verastem Presents Data at the 2014 American Society of Hematology Annual Meeting verastem.com ↗
B-ALLs with IKZF1 mutations may be resistan |
| 2014-11-07 | Verastem, Inc. | Results Scientific Data on PYK2 Inhibition by VS-4718 in Multiple Myeloma Published in the Journal Blood verastem.com ↗
In the published study, it was demonstrated that inhibition of PYK2 led to reduction of myeloma tumor growth in vivo as well as decreased cell proliferation, cell cycle progression, and adhesion ability in vitro. |
All press releases naming this drug 10 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VS-4718 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02215629 ↗ |
| Known as | PND-1186 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3040440 ↗ |
| Known as | SR-2516 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3040440 ↗ |
| Action | Inhibit | “VS-4718, a focal adhesion kinase inhibitor” NCT01849744 ↗1“Focal adhesion kinase 1 inhibitor” CHEMBL3040440 ↗ |
| Modality | Small molecule | — CHEMBL3040440 ↗ |
| Route | Oral | “Oral VS-4718 administered BID (QD during first cohort) during a 28 day cycle.” NCT01849744 ↗ |
| Target | PTK2 | “Focal adhesion kinase 1 inhibitor” CHEMBL3040440 ↗ |